title: [Clinical application of different sedation regimen in patients with septic shock].
abstract: OBJECTIVE
  To evaluated the 3 sedation regimen for patients with septic shock.
  
  
  METHODS
  The randomized controlled trial wan conducted. Forty-five patients with septic shock were assigned to 3 groups (midazolam group, propofol group, and dexmedetomidine group) randomly. The basic characteristics of patients, the duration of mechanical ventilation, the length of stay in the ICU, the death rate for 28 days and the regulatory cell (Treg) in peripheral blood were observed. The control group for Treg test was consisted of 20 healthy volunteers.
  
  
  RESULTS
  There were no significant differences between the groups in the death rate for 28 days and the duration of mechanical ventilation. The length of stay in the ICU in dexmedetomidine group was shorter than that in midazolam group(15.21±5.55 vs.19.67±5.7 days, P<0.05). The Treg of 3 groups was higher than that of control group (11.82±4.93 vs.3.69±1.71, 11.30±3.42 vs. 3.69±1.71, 12.83±6.17 vs. 3.69±1.71) at the first day of ICU. The Treg after 3 ICU days in dexmedetomidine group and the Treg after 5 ICU days in propofol group and in midazolam group have no difference with control group.
  
  
  CONCLUSIONS
  For the patients with septic shock, dexmedetomidine could decrease the length of stay in the ICU and the duration of immune suppression.
authors.affiliation: Intensive Care Unit, Sir Run Run Shaw Hospital Affiliated School of Medicine, Zhejiang University, Hangzhou 310016, China.
authors.forename: F
authors.initials: F
authors.lastname: Guo
authors.forename: Q
authors.initials: Q
authors.lastname: Wang
authors.forename: C Y
authors.initials: CY
authors.lastname: Yan
authors.forename: H Y
authors.initials: HY
authors.lastname: Huang
authors.forename: X
authors.initials: X
authors.lastname: Yu
authors.forename: L Y
authors.initials: LY
authors.lastname: Tu
mesh_terms: D000758:Anesthesia; D016292:Procedural Sedation; D020927:Dexmedetomidine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D007362:Intensive Care Units; D007902:Length of Stay; D008297:Male; D008874:Midazolam / Q000009:adverse effects / Q000627:therapeutic use*; D015742:Propofol / Q000009:adverse effects / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012772:Shock, Septic / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine; D008874:Midazolam; D015742:Propofol